Biogen's daxdilimab reduces disease activity in moderate-to-severe discoid lupus trial
Biogen's experimental monoclonal antibody daxdilimab demonstrated significant reduction in disease activity with favorable safety profile in Phase 2 trial for patients with moderate-to-severe discoid lupus erythematosus.
